Near-Term BioPharma Profitability: Must-Have or Distraction?

Being profitable has its advantages, particularly in the current biopharma funding environment-and particularly for those companies able to leverage relatively small investment into relatively quick profitability. But for firms whose own pipelines have yet to come to fruition, it also imposes constraints and pressures on management that wouldn't otherwise be there. In Vivo Europe Rx looks at how four of Europe's biopharma firms became profitable, and how this has affected company strategy. Their differences lie precisely in the purpose of their early profits-as a means to an end, or as the end in itself.